Israel’s life-science industry posted a record year in total deal size as companies benefited from a boom in U.S. investment, PricewaterhouseCoopers Israel said in a report.
U.S. Pharmaceutical and Life Sciences
Health-care companies, with $2.5 billion in transactions, grabbed the biggest share of $7.6 billion in Israeli technology deals worldwide this year, PwC Israel said. That was up 92 percent from $1.3 billion in 2012, according to the report.
Israeli companies, which stayed on the sidelines following the 2008 global financial crisis, experienced a major thaw in the IPO market in 2013. In June, Kadimastem Ltd. (KDST), a developer of stem-cell therapies, became the first company to list on the Israeli bourse since the end of 2011 after a record 56 IPOs in 2007, exchange data show.
No comments:
Post a Comment